Cartesian Therapeutics, Inc. (RNAC) Operating income 2016–2025
Cartesian Therapeutics, Inc. (RNAC) annual operating income history from SEC filings — each fiscal year as reported.
-$143.4MFY2025 · since FY2016: -$34.7M → -$143.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$143.4M | -226.7% |
| FY2024 | -$43.9M | +49.2% |
| FY2023 | -$86.4M | -694.4% |
| FY2022 | $14.5M | +416.2% |
| FY2021 | -$4.6M | +91.9% |
| FY2020 | -$56.8M | -8.3% |
| FY2019 | -$52.5M | +19.3% |
| FY2018 | -$65.0M | -1.9% |
| FY2017 | -$63.8M | -84.0% |
| FY2016 | -$34.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net incomeRNAC Net marginRNAC Gross profitRNAC Gross marginRNAC Operating marginRNAC Operating cash flowRNAC Free cash flowRNAC Capital expendituresRNAC Return on equityRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Total liabilitiesRNAC Shareholders’ equityRNAC overview →